moxifloxacin has been researched along with mocetinostat in 3 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 21,735 | 390 | 8,606 |
| Protein | Taxonomy | moxifloxacin (IC50) | mocetinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Eick, S; Guentsch, A; Hoffmann, T; Jentsch, H; Pfister, W | 1 |
| King, LB; Marquart, ME; Norcross, EW; Sanders, ME; Taylor, SD; Tolo, I; Tullos, NA | 1 |
| Dogan, A; Donmez, F | 1 |
1 trial(s) available for moxifloxacin and mocetinostat
| Article | Year |
|---|---|
Moxifloxacin as an adjunctive antibiotic in the treatment of severe chronic periodontitis.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteroides; Chronic Periodontitis; Colony Count, Microbial; Combined Modality Therapy; Dental Scaling; Doxycycline; Female; Fluoroquinolones; Follow-Up Studies; Gingival Hemorrhage; Humans; Interleukin-8; Leukocyte Elastase; Male; Moxifloxacin; Periodontal Attachment Loss; Periodontal Pocket; Peroxidase; Porphyromonas gingivalis; Prospective Studies; Quinolines; Root Planing; Treatment Outcome; Treponema denticola | 2008 |
2 other study(ies) available for moxifloxacin and mocetinostat
| Article | Year |
|---|---|
Moxifloxacin and cholesterol combined treatment of pneumococcal keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Cholesterol; Disease Models, Animal; Drug Therapy, Combination; Fluoroquinolones; Keratitis; Moxifloxacin; Peroxidase; Quinolines; Rabbits; Severity of Illness Index; Stem Cells; Streptococcus pneumoniae; Treatment Outcome | 2010 |
Investigation of the effects of three different generations of fluoroquinolone derivatives on antioxidant and immunotoxic enzyme levels in different rat tissues.
Topics: Adenosine Deaminase; Animals; Antioxidants; Aspartate Aminotransferases; Catalase; Ciprofloxacin; COVID-19; Creatinine; Fluoroquinolones; Glucose; Glutathione; Glutathione Peroxidase; Levofloxacin; Lipid Peroxidation; Malondialdehyde; Moxifloxacin; Nalidixic Acid; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; SARS-CoV-2; Superoxide Dismutase; Triglycerides | 2022 |